Ming Yu Cao

Title: The Innovative Contributions of Ming Yu Cao

Introduction

Ming Yu Cao is a notable inventor based in Mississauga, Canada. He has made significant contributions to the field of cancer treatment through his innovative research and patents. His work focuses on the use of interleukin 17E as a therapeutic agent in inhibiting tumor growth.

Latest Patents

Ming Yu Cao holds a patent for the "Use of interleukin 17E for the treatment of cancer." This patent describes the application of interleukin 17E to inhibit tumor growth in subjects. The interleukin 17E can be administered exogenously, either as a polypeptide or a polynucleotide encoding the polypeptide. Additionally, it can stimulate the production of endogenous interleukin 17E. The patent also outlines the use of interleukin 17E in combination with various anti-cancer therapeutics, including standard chemotherapeutic drugs, immunotherapeutics, radiation, gene therapy, hormone manipulation, and antisense therapy. Ming Yu Cao has 1 patent to his name.

Career Highlights

Throughout his career, Ming Yu Cao has worked with prominent companies in the biotechnology sector. He has been associated with Lorus Therapeutics Inc. and Aptose Biosciences Inc., where he contributed to advancing cancer treatment methodologies. His expertise in the field has made him a valuable asset to these organizations.

Collaborations

Ming Yu Cao has collaborated with several professionals in his field, including Jim A Wright and Aiping H Young. These collaborations have further enhanced his research and development efforts in cancer therapeutics.

Conclusion

Ming Yu Cao's innovative work in the treatment of cancer through the use of interleukin 17E showcases his dedication to advancing medical science. His contributions are significant in the ongoing fight against cancer, and his patent reflects the potential for new therapeutic approaches.